<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407003</url>
  </required_header>
  <id_info>
    <org_study_id>CLIK066X2101</org_study_id>
    <nct_id>NCT01407003</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 4-part, Interwoven Single- and Multiple-ascending Dose Study to Assess Safety, Tolerability, PK and PD of LIK066 in Healthy Subjects and in Patients With T2DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess safety, tolerability, and effect of LIK066 on blood glucose in healthy&#xD;
      subjects and in patients with T2DM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single and multiple dose(s) of LIK066: number of patients with adverse events and changes from baseline in vital signs, ECG and clinical labs (blood chemistry, hematology and urinalysis).</measure>
    <time_frame>Daily during treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting and post-challenge plasma glucose after 2 weeks of treatment</measure>
    <time_frame>Baseline and End of Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: to measure the study drug concentration in blood and urine samples to be collected after drug administration</measure>
    <time_frame>Day 1 and End of Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting and post-challenge plasma glucose after a single dose and 2 weeks of treatment</measure>
    <time_frame>Baseline and End of Treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Type 2 Diabetes Mellitus (T2DM)</condition>
  <arm_group>
    <arm_group_label>LIK066 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo in healthy subjects</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 in patients with type 2 diabetes mellitus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo in patients with type 2 diabetes mellitus</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIK066</intervention_name>
    <description>Participants will receive a single or multiple doses of LIK066</description>
    <arm_group_label>LIK066 in healthy subjects</arm_group_label>
    <arm_group_label>LIK066 in patients with type 2 diabetes mellitus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive a single or multiple doses of a matching placebo</description>
    <arm_group_label>Matching placebo in healthy subjects</arm_group_label>
    <arm_group_label>Matching placebo in patients with type 2 diabetes mellitus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parts I and III: Healthy male and female subjects age 18 to 55 years of age included,&#xD;
             and in good health as determined by past medical history, physical examination,&#xD;
             electrocardiogram, and laboratory tests at screening.&#xD;
&#xD;
          -  Parts II and IV: Patients, age 18-65 years, must have been diagnosed with T2DM at&#xD;
             least 8 weeks prior to screening with HbA1c 6.5 to 10.0%, inclusive, at screening.&#xD;
&#xD;
          -  Fasting plasma glucose â‰¤250mg/dL at screening and baseline.&#xD;
&#xD;
          -  If treated with metformin, patients must be on a stable dose for 12 weeks prior to&#xD;
             randomization and maintain the dose until the end of the study.&#xD;
&#xD;
        Exclusion Criteria; all parts:&#xD;
&#xD;
          -  Patients with type 1 diabetes mellitus.&#xD;
&#xD;
          -  Patients with history of acute diabetic complications within the 6 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Women of child-bearing potential.&#xD;
&#xD;
          -  Patients with signs or symptoms of significant diabetic complications.&#xD;
&#xD;
          -  Patients treated with certain blood pressure or lipid lowering medications unless&#xD;
             patients have been on stable doses for the 12 weeks prior to dosing.&#xD;
&#xD;
          -  History of drug or alcohol abuse within the 12 months prior to dosing.&#xD;
&#xD;
          -  Any surgical or medical condition, acute or unstable chronic disease which may, based&#xD;
             on the investigator's opinion, jeopardize the patient in case of participation in the&#xD;
             study.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11104</url>
    <description>Results for CLIK066X2101 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>July 20, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <disposition_first_submitted>March 27, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 27, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 24, 2014</disposition_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T2DM, blood glucose, OGTT, LIK066</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Licogliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

